Dose-finding Study for SAR442168 in Relapsing Multiple Sclerosis

Relapsing Multiple Sclerosis Clinical Trial

Official title:

A Phase 2b Dose-finding Study for SAR442168, a Bruton's Tyrosine Kinase Inhibitor, in Participants With Relapsing Multiple Sclerosis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03889639
• Other study ID #: DRI15928
• Secondary ID: 2018-003927-12U1
• Status: Completed
• Phase: Phase 2
• Start date: March 29, 2019
• Est. completion date: January 2, 2020

Study information

• Verified date: March 2023
• Source: Sanofi
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Primary Objective:

To determine the dose-response relationship for SAR442168 to reduce the number of new active brain lesions.

Secondary Objectives:

• To evaluate efficacy of SAR442168 on disease activity as assessed by imaging measures.

• To evaluate the safety and tolerability of SAR442168.

Description:

The total study duration was 24 weeks which included a screening period of 4 weeks, a treatment period of 16 weeks, and a follow-up period of up to 4 weeks. Participants who completed the Week 16 visit were proposed to be enrolled in a long-term extension safety and efficacy study to assess safety, tolerability and efficacy of SAR442168.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 130
• Est. completion date: January 2, 2020
• Est. primary completion date: January 2, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 55 Years

Eligibility

Inclusion criteria:

• Participant must be 18 to 55 years of age, inclusive, at the time of signing the informed consent.

• Participant was diagnosed with relapsing multiple sclerosis (RMS) according to the 2017 revision of the McDonald diagnostic criteria.

• Participant must had at least 1 documented relapse within the previous year, OR greater than or equal to (>=) 2 documented relapses within the previous 2 years, OR >=1 active Gadolinium (Gd) enhancing brain lesion on an MRI scan in the past 6 months and prior to screening.

• A female participant must had used a double contraception method including a highly effective method of birth control from inclusion and up to 2 months after the last study dose, except if she had undergone sterilization at least 3 months earlier or was postmenopausal. Menopause was defined as being amenorrheic for >=12 months with serum follicle-stimulating hormone (FSH) level greater than (>) 30 International Units per liters.

• Male participants, whose partners were of childbearing potential (including breastfeeding women), must had accepted to use, during sexual intercourse, a double contraceptive method according to the following algorithm: (condom) plus (intrauterine device or hormonal contraceptive) from inclusion up to 3 months after the last dose.

• Male participants whose partners were pregnant must had used, during sexual intercourse, a condom from inclusion up to 3 months after the last dose.

• Male participants had agreed not to donate sperm from the inclusion up to 3 months after the last dose.

• Participant had given written informed consent prior to undertaking any study-related procedure.

Exclusion criteria:

• The participant had been diagnosed with primary progressive multiple sclerosis according to the 2017 revision of the McDonald diagnostic criteria or with non relapsing secondary progressive multiple sclerosis.

• Requirement for concomitant treatment that could bias the primary evaluation.

• Contraindication for MRI.

• Contraindications to use MRI Gd contrast-enhancing preparations.

• History of infection with the human immunodeficiency virus (HIV).

• History of active or latent tuberculosis.

• Any other active infections that would adversely affect participation or investigational medicinal product administration in this study, as judged by the Investigator.

• Presence of any screening laboratory or electrocardiogram values outside normal limits that were considered in the Investigator's judgment to be clinically significant.

• Presence of liver injury.

• At screening, the participant was positive for hepatitis B surface antigen and/or hepatitis B core antibody and/or was positive for hepatitis C antibody.

• Bleeding disorder or known platelet dysfunction at any time prior to screening visit.

• Participant had received any live (attenuated) vaccine (including but not limited to varicella zoster, oral polio, and nasal influenza) within 2 months before first treatment visit.

• Participant was receiving strong inducers or inhibitors of cytochrome P450 3A (CYP3A) or CYP2C8 hepatic enzymes.

• Participant was receiving anticoagulant/antiplatelet therapies.

• Participant had taken other investigational drugs within 3 months or 5 half lives, whichever was longer, before screening visit.

• Participant had an Expanded Disability Status Scale score >5.5 at first screening visit.

• Participant had a relapse in the 30 days prior to randomization.

• Participant was pregnant or a breastfeeding woman.

• History or presence of significant other concomitant illness.

• The participant had received medications/treatments for multiple sclerosis within a specified time frame.

The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Related Conditions & MeSH terms

• Multiple Sclerosis
• Relapsing Multiple Sclerosis
• Sclerosis

Intervention

Drug:
• SAR442168
Pharmaceutical form: Film coated tablet; Route of administration: Oral
• Placebo
Pharmaceutical form: Film coated tablet; Route of administration: Oral
• Locally approved intravenous contrast medium for contrast enhanced magnetic resonance imaging (MRI)
Pharmaceutical form: Solution for injection; Route of administration: Intravenous

Locations

Country	Name	City	State
Canada	Investigational Site Number 1240002	Gatineau
Canada	Investigational Site Number 1240001	Greenfield Park
Canada	Investigational Site Number 1240003	Vancouver
Czechia	Investigational Site Number 2030007	Brno
Czechia	Investigational Site Number 2030004	Hradec Kralove
Czechia	Investigational Site Number 2030003	Jihlava
Czechia	Investigational Site Number 2030005	Ostrava - Poruba
Czechia	Investigational Site Number 2030006	Pardubice
Czechia	Investigational Site Number 2030001	Praha 2
Czechia	Investigational Site Number 2030002	Praha 5 - Motol
Estonia	Investigational Site Number 2330001	Tallinn
France	Investigational Site Number 2500004	Nancy Cedex
France	Investigational Site Number 2500001	Nantes Cedex 1
France	Investigational Site Number 2500002	Strasbourg Cedex
France	Investigational Site Number 2500003	Toulouse Cedex 9
Netherlands	Investigational Site Number 5280001	Amsterdam
Netherlands	Investigational Site Number 5280002	Sittard-Geleen
Russian Federation	Investigational Site Number 6430006	Kazan
Russian Federation	Investigational Site Number 6430002	Moscow
Russian Federation	Investigational Site Number 6430003	Moscow
Russian Federation	Investigational Site Number 6430001	Saint-Petersburg
Russian Federation	Investigational Site Number 6430004	St-Petersburg
Russian Federation	Investigational Site Number 6430005	St-Petersburg
Russian Federation	Investigational Site Number 6430007	Tyumen
Slovakia	Investigational Site Number 7030001	Bratislava
Slovakia	Investigational Site Number 7030002	Martin
Spain	Investigational Site Number 7240006	Barakaldo
Spain	Investigational Site Number 7240002	Barcelona
Spain	Investigational Site Number 7240001	Madrid
Spain	Investigational Site Number 7240004	Murcia
Spain	Investigational Site Number 7240005	Salt
Spain	Investigational Site Number 7240003	Sevilla
Ukraine	Investigational Site Number 8040002	Chernivtsi
Ukraine	Investigational Site Number 8040005	Dnipro
Ukraine	Investigational Site Number 8040001	Lviv
Ukraine	Investigational Site Number 8040006	Lviv
Ukraine	Investigational Site Number 8040009	Odesa
Ukraine	Investigational Site Number 8040003	Vinnytsya
Ukraine	Investigational Site Number 8040007	Zhytomyr
United States	Investigational Site Number 8400005	Cullman	Alabama
United States	Investigational Site Number 8400008	Dayton	Ohio
United States	Investigational Site Number 8400003	Knoxville	Tennessee
United States	Investigational Site Number 8400002	Maitland	Florida
United States	Investigational Site Number 8400001	Northbrook	Illinois
United States	Investigational Site Number 8400007	Savannah	Georgia
United States	Investigational Site Number 8400004	Sunrise	Florida
United States	Investigational Site Number 8400009	Tampa	Florida
United States	Investigational Site Number 8400006	Westerville	Ohio

Sponsors (1)

Lead Sponsor	Collaborator
Sanofi

Countries where clinical trial is conducted

United States,  Canada,  Czechia,  Estonia,  France,  Netherlands,  Russian Federation,  Slovakia,  Spain,  Ukraine, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Brain Magnetic Resonance Imaging (MRI) Assessment: Number of New Gadolinium (Gd) Enhancing T1-hyperintense Lesions	Number of new Gd-enhancing T1-hyperintense lesions was detected by brain MRI at the end of 12 weeks of SAR442168 treatment (i.e., at Week 12 for Cohort 1 participants and Week 16 for Cohort 2 participants). Data was planned to be collected and analyzed on pooled population of participants at each dose level of SAR442168 (either in Cohort 1 and 2) and pooled population of participants receiving placebo in Cohort 2 and was not planned to collected during placebo administration in Cohort 1 (Weeks 12 to 16).	After 12 weeks of SAR442168 treatment for SAR442168 reporting arms (i.e., at Week 12 for Cohort 1 participants, at Week 16 for Cohort 2 participants) and at Week 4 for Cohort 2 placebo
Secondary	Number of New or Enlarging T2 Lesions	Number of new and enlarging T2 lesions was detected by brain MRI at the end of 12 weeks of SAR442168 treatment (i.e., at Week 12 for Cohort 1 participants and Week 16 for Cohort 2 participants).	After 12 weeks of SAR442168 treatment for SAR442168 reporting arms (i.e., at Week 12 for Cohort 1 participants, at Week 16 for Cohort 2 participants), and at Week 4 for Cohort 2 placebo
Secondary	Total Number of Gd-enhancing T1-hyperintense Lesions	Total number of Gd-enhancing T1-hyperintense lesions was detected by brain MRI at the end of 12 weeks of SAR442168 treatment (i.e., at Week 12 for Cohort 1 participants and Week 16 for Cohort 2 participants).	After 12 weeks of SAR442168 treatment for SAR442168 reporting arms (i.e., at Week 12 for Cohort 1 participants, at Week 16 for Cohort 2 participants), and at Week 4 for Cohort 2 placebo
Secondary	Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs): Weeks 1-4 Period	Adverse event (AE) was defined as any unfavorable and unintended sign, symptom, or disease temporally associated with use of study drug. Serious AE (SAE) was defined as any untoward medical occurrence that, at any dose resulted in death, life-threatening, inpatient hospitalization or prolongation of existing hospitalization, disability/incapacity, congenital anomaly/birth defect, or medical event. TEAEs were defined as AEs (serious/non-serious) that developed, worsened, or became serious during on-treatment period (for this outcome measure- "Weeks 1 to 4 period": time from 1st administration of study drug to Week 4). Cohorts 1 and 2 received SAR442168 and placebo for first 4 weeks, respectively.	From Baseline up to Week 4
Secondary	Number of Participants With Treatment-emergent Adverse Events and Treatment-emergent Serious Adverse Events: SAR442168 Treatment Period	AE was defined as any unfavorable and unintended sign (including abnormal laboratory finding), symptom, or disease temporally associated with use of study drug. SAE was defined as any untoward medical occurrence that, at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, persistent disability/incapacity, congenital anomaly/birth defect, or medical event. TEAEs: AEs that developed, worsened, or became serious during on-treatment period (for this outcome measure defined as "SAR442168 treatment period" which was considered as Weeks 1 to 12 for Cohort 1 and Weeks 4 to 16 for Cohort 2).	Weeks 1 to 12 for Cohort 1 participants and Weeks 4 to 16 for Cohort 2 participants
Secondary	Number of Participants With Individual Clinically Relevant Abnormalities in Laboratory Tests (Hematology, Chemistry, Urinalysis), Vital Signs, and Electrocardiograms (ECG)	Individual clinically relevant abnormalities was defined as potentially clinically significant abnormalities (PCSA) considered as SAEs or TEAEs leading to study treatment discontinuation or study discontinuation during the on-treatment period (time from first study drug administration until Week 16), considering all evaluations performed during the on-treatment period that included unscheduled or repeated evaluations.	Baseline up to Week 12 for Cohort 1 participants; Baseline up to Week 4 for Cohort 2 Placebo and from Weeks 4 to 16 for Cohort 2 SAR442168 receiving participants